Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With Ascites (ECF)

NCT01552590 Phase 4 TERMINATED

This study is to evaluate the efficacy of a 2-week course of tolvaptan in improving serum sodium and the excretion of extracellular fluid in liver cirrhotic patients with ascites and hyponatremia

Details

Lead sponsor	Korea Otsuka Pharmaceutical Co., Ltd.
Phase	Phase 4
Status	TERMINATED
Enrolment	74
Start date	2012-04
Completion	2012-04

Conditions

• Hyponatremia and Extracellular Fluid in Cirrhotic

Interventions

• Tolvaptan
• Placebo

Primary outcomes

• Serum Na — 2 weeks (Baseline, Day 14)

Countries

South Korea